EPS for Cerus Corporation (CERS) Expected At $-0.11

July 11, 2018 - By Christine McCrea

Investors sentiment increased to 1.84 in Q1 2018. Its up 0.39, from 1.45 in 2017Q4. It is positive, as 5 investors sold Cerus Corporation shares while 27 reduced holdings. 21 funds opened positions while 38 raised stakes. 69.09 million shares or 17.19% more from 58.96 million shares in 2017Q4 were reported.
Swiss State Bank holds 221,900 shares. Lesa Sroufe & reported 2.46% of its portfolio in Cerus Corporation (NASDAQ:CERS). Proshare Advsrs owns 74,624 shares or 0% of their US portfolio. Teacher Retirement System Of Texas reported 28,236 shares. Vanguard Gp Incorporated Inc holds 5.87M shares or 0% of its portfolio. Fincl Bank Of America Corporation De invested in 0% or 606,597 shares. Schwab Charles Inv Mngmt Inc has invested 0% in Cerus Corporation (NASDAQ:CERS). 42,000 are owned by First Manhattan. Menta Cap Lc holds 0.06% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 50,200 shares. Garde owns 13,385 shares. 48,150 are owned by Premier Asset Mngmt Ltd Com. Ardsley Advisory holds 0.07% or 80,000 shares in its portfolio. California Pub Employees Retirement Sys invested 0% in Cerus Corporation (NASDAQ:CERS). 53,221 are owned by Price T Rowe Assocs Inc Md. 10.75M are owned by Baker Bros Advisors L P.

Since March 10, 2018, it had 1 insider buy, and 11 selling transactions for $1.32 million activity. The insider ANDERSON TIMOTHY B sold $152,950. 17,766 shares valued at $87,795 were sold by Greenman William Mariner on Saturday, March 10. On Monday, June 4 the insider Moore Carol sold $504,077. Shares for $23,409 were sold by Green Kevin Dennis on Saturday, March 10. $773,199 worth of Cerus Corporation (NASDAQ:CERS) was bought by CORASH LAURENCE M on Monday, March 12. Menard Chrystal sold $22,793 worth of Cerus Corporation (NASDAQ:CERS) on Saturday, March 10.

Analysts expect Cerus Corporation (NASDAQ:CERS) to report $-0.11 EPS on August, 2.They anticipate $0.05 EPS change or 31.25 % from last quarter’s $-0.16 EPS. After having $-0.11 EPS previously, Cerus Corporation’s analysts see 0.00 % EPS growth. The stock decreased 0.99% or $0.07 during the last trading session, reaching $6.99. About 411,182 shares traded. Cerus Corporation (NASDAQ:CERS) has risen 221.29% since July 12, 2017 and is uptrending. It has outperformed by 208.72% the S&P500.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 2 analysts covering Cerus Corp (NASDAQ:CERS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cerus Corp had 3 analyst reports since January 24, 2018 according to SRatingsIntel. The stock has “Buy” rating by Robert W. Baird on Wednesday, January 24. Cantor Fitzgerald maintained Cerus Corporation (NASDAQ:CERS) on Tuesday, May 8 with “Buy” rating. The company was maintained on Thursday, March 8 by Cantor Fitzgerald.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $912.50 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Another recent and important Cerus Corporation (NASDAQ:CERS) news was published by Globenewswire.com which published an article titled: “Report: Developing Opportunities within Torchmark, Cerus, American Equity Investment Life Holding, Southern Copper …” on June 28, 2018.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: